Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss seasonal vaccination planning and survey findings on laboratory industry growth. Later, Leslie Donato, Ph.D., a clinical chemist at Mayo Clinic, shares how an innovative testing panel is improving the diagnosis of bile acid malabsorption.
Learn how documenting and managing client relationships strengthens retention, supports growth, and creates a competitive advantage.
Explore why traditional microscopy is challenging, how AI-assisted review works, what workflow changes are required, and how validation data can support implementation decisions.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss “rabbit fever” cases in New York and strategies for responding to industry trends. Later, Dr. Pritt welcomes Mary Jo Williamson, Mayo Clinic Laboratories’ chief administrative officer, to share practical strategies for leading teams through periods of rapid change.
Learn more about how Mayo Clinic’s Nerve Pathology Laboratory leverages decades of nerve pathology testing experience and unmatched clinical expertise to provide diagnostic clarity for rare and complex neuropathies.
A new survey highlights four strategies laboratories are using to navigate challenges, strengthen services, and fuel growth.
Find out how our suite of autoimmune movement disorder testing can help diagnose PDE10A autoimmunity in patients who present with hyperkinetic movement disorders.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and recent reports about the New World screwworm. Dr. Morice also shares insights on building an innovation strategy that delivers meaningful organizational value.
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Learn how our suite of testing reveals the cause of bile acid-induced diarrhea in a 66-year-old woman.
Recording coming soon. Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.
Register now–Oct. 13, 2026 Review key federal legislative and regulatory developments affecting clinical laboratories.
Discuss ways to increase transparency in the workplace to maintain a safe, honest working relationship between colleagues.